Tempus AI, Inc. (NASDAQ:TEM) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have been assigned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $71.8333.

TEM has been the subject of several analyst reports. Morgan Stanley raised their target price on shares of Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, August 12th. Guggenheim raised their target price on shares of Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, September 26th. Piper Sandler reiterated a “neutral” rating on shares of Tempus AI in a report on Friday, August 8th. BTIG Research lifted their price objective on shares of Tempus AI from $75.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, August 20th. Finally, Bank of America lifted their price objective on shares of Tempus AI from $68.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, June 25th.

Tempus AI Price Performance

Tempus AI stock opened at $87.99 on Thursday. The firm has a 50-day moving average price of $73.92 and a 200-day moving average price of $62.59. The firm has a market capitalization of $15.29 billion, a PE ratio of -73.94 and a beta of 4.89. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58. Tempus AI has a 12-month low of $31.36 and a 12-month high of $97.79.

Tempus AI (NASDAQ:TEM) last released its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The firm had revenue of $314.64 million during the quarter, compared to analyst estimates of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The business’s revenue was up 89.5% on a year-over-year basis. During the same quarter last year, the business earned ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Tempus AI will post -6.15 EPS for the current year.

Insider Activity at Tempus AI

In related news, EVP Erik Phelps sold 3,664 shares of Tempus AI stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $273,517.60. Following the completion of the sale, the executive vice president owned 94,115 shares in the company, valued at $7,025,684.75. This trade represents a 3.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Eric P. Lefkofsky sold 332,500 shares of Tempus AI stock in a transaction dated Thursday, September 25th. The shares were sold at an average price of $76.56, for a total transaction of $25,456,200.00. Following the sale, the chief executive officer owned 9,141,032 shares of the company’s stock, valued at $699,837,409.92. The trade was a 3.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 933,662 shares of company stock worth $67,909,393 over the last ninety days. 26.27% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEM. Concord Wealth Partners increased its position in Tempus AI by 308.0% during the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after purchasing an additional 308 shares during the period. Allworth Financial LP increased its position in Tempus AI by 5,000.0% during the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. Cherry Tree Wealth Management LLC purchased a new position in Tempus AI during the 1st quarter valued at about $31,000. SouthState Corp increased its position in Tempus AI by 3,761.5% during the 2nd quarter. SouthState Corp now owns 502 shares of the company’s stock valued at $32,000 after purchasing an additional 489 shares during the period. Finally, University of Texas Texas AM Investment Management Co. purchased a new position in Tempus AI during the 1st quarter valued at about $33,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.